Peregrine Pharmaceut (PPHMP) 22.92 $PPHMP Avid

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Peregrine Pharmaceut (PPHMP) 22.92 $PPHMP

Avid Bioservices to Participate in Cambridge Healthtech Institute's (CHI) 8th Annual The Bioprocessing Summit
GlobeNewswire - Tue Aug 09, 7:05AM CDT
Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), today announced that the company will have a significant presence at Cambridge Healthtech Institute's (CHI) 8 Annual The Bioprocessing Summit, being held August 15-19, 2016 in Boston, MA. The company's vice president of process sciences, Pete Gagnon, will make a presentation centered on the role of protein A in biomanufacturing and will serve as one of three expert participants for a panel discussion on technology advancements that can assist biological drug manufacturers in achieving optimal viral clearance during the performance of downstream purification processes.
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)

Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
GlobeNewswire - Thu Jun 02, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NasdaqPHM) (NasdaqPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock".
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)

Peregrine Pharmaceuticals Provides Corporate Update Highlighting Latest Developments for Contract Manufacturing and Drug Development Businesses
GlobeNewswire - Thu Jun 02, 7:05AM CDT
- Contract Manufacturing Revenue Hits All-Time High of $44 Million for Fiscal Year Ended April 2016; Fiscal Year 2017 Contract Manufacturing Revenue Projected Between $50-55 Million; Continued Growth Expected to Lead to Future Sustainable Profitability in 24 Months -
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)

Avid Bioservices to Exhibit at the 2016 BIO International Convention
Marketwired - Tue May 31, 7:05AM CDT
Showcasing Expanded Contract Manufacturing Capabilities From Early Stage Development to Commercialization; Onsite Access to Leading Biopharmaceutical Manufacturing Experts
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)

Avid Bioservices Appoints Pete Gagnon as Vice President of Process Sciences
Marketwired - Mon May 23, 7:05AM CDT
Leading Innovator in Field of Biologics Purification Brings Unique Manufacturing Experience to Broaden Avid's Capabilities, Including Biosimilar Expertise
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)

Preclinical Data Presented at American Association for Cancer Research (AACR) Annual Meeting Demonstrate Enhanced Therapeutic Benefit of Combining a PS-Targeting Antibody With Anti-PD-1 Therapy in Models of Triple Negative Breast Cancer (TNBC)
GlobeNewswire - Wed Apr 20, 7:05AM CDT
- Statistically Significant Improvement in Overall Survival for Combination as Compared to Anti-PD-1 Therapy Alone in TNBC Models; Combination Also Protects Against Re-Challenge With TNBC Tumor Cells -
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)

Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab
GlobeNewswire - Wed Jan 06, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced a new research collaboration with the National Comprehensive Cancer Network(R) (NCCN(R)) to expand the company's ongoing clinical research and development of bavituximab for the treatment of a range of tumors. NCCN, a not-for-profit alliance of 26 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Peregrine will fund multiple investigator-initiated clinical and correlative studies with bavituximab in multiple cancers at NCCN Member Institutions and their affiliate community hospitals through a $2 million research grant to NCCN's Oncology Research Program (ORP). NCCN will be responsible for oversight and monitoring of the clinical studies through the research grant.
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)

Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2016 and Recent Developments
GlobeNewswire - Thu Dec 10, 3:05PM CST
--Peregrine and AstraZeneca Expand Immuno-Oncology Collaboration and Plan Phase II NSCLC Trial--
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)

Peregrine Pharmaceuticals' board to pay USD0.65625 per preferred share dividend
M2 - Tue Dec 08, 3:44AM CST
The board of directors of Peregrine Pharmaceuticals (NasdaqPHMP) declared on Monday its quarterly dividend of USD0.65625 per share on its 10.50% Series E convertible preferred stock accruing from 1 October 2015 through 31 December 2015.
PPHMP: 22.92 (+0.25)

Peregrine to Report Financial Results for Second Quarter of Fiscal Year 2016 After Market Close on December 10, 2015
GlobeNewswire - Thu Dec 03, 3:05PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the second quarter of fiscal year 2016 ended October 31, 2015 on December 10, 2015 after market and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Peregrine's senior management will discuss financial results for the second quarter and review the recent progress of its clinical development programs.
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)

Peregrine Pharmaceuticals to Participate in Two Upcoming Life Science Investor Conferences
GlobeNewswire - Mon Nov 23, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that the company will participate in two upcoming life science investor conferences being held in New York during the month of December. Steven W. King, president and chief executive officer, will participate in a panel discussion focused on cancer immunotherapy at Piper Jaffray's 27 Annual Healthcare Conference. Additionally, the company will be one of only 16 life science companies attending Roth Capital Partners' Immuno-Oncology Corporate Access Day.
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)

New Preclinical Data Presented at SITC Annual Meeting Highlight Bavituximab's Enhanced Anti-Tumor Activity When Combined With Checkpoint Inhibitors in Breast Cancer and Melanoma
GlobeNewswire - Mon Nov 09, 7:05AM CST
- Bavituximab in Combination with Anti-PD-1 in Breast Cancer Studies Showed a Statistically Significant Improvement in Overall Survival as Compared to Subjects Receiving Anti-PD-1 Therapy Alone -
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)

AstraZeneca and Peregrine Pharmaceuticals Expand Ongoing Immuno-Oncology Collaboration to Include Phase II Lung Cancer Combination Clinical Trial
GlobeNewswire - Thu Oct 15, 7:05AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it has expanded its ongoing cancer immunotherapy clinical collaboration with AstraZeneca to include a second, later-stage trial. The companies will now also evaluate the immunotherapy combination of Peregrine's phosphatidylserine (PS)-targeted immune-activator, bavituximab, and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), in a global Phase II study in patients with previously treated squamous or non-squamous non-small cell lung cancer (NSCLC). The randomized Phase II trial will be conducted by Peregrine.
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)

New Translational Data Highlights Bavituximab's Ability to Induce Signs of Immune Activation in Lung Cancer Tumor Samples With Negative PD-L1 Expression
GlobeNewswire - Tue Sep 08, 7:08AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced positive new data from a translational study of bavituximab, the company's investigational phosphatidylserine (PS)-signaling pathway inhibitor. Findings demonstrated the ability of bavituximab, alone or in combination with docetaxel, to induce signs of immune activation in non-small cell lung cancer (NSCLC) patient-derived tumor samples, particularly when there was negative PD-L1 expression in the tumor sample. These data further support the potential mechanistic synergies for bavituximab with chemotherapy and checkpoint inhibitors targeting the PD-1/PD-L1 pathway. Results from the study are being presented as part of a mini-oral presentation at the International Association for the Study of Lung Cancer's (IASLC's) World Conference on Lung Cancer (WCLC), being held this week in Denver, Colorado.
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)

Peregrine to Report Financial Results for First Quarter of Fiscal Year 2016 After Market Close on September 9, 2015
GlobeNewswire - Thu Sep 03, 3:05PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the first quarter of fiscal year 2016 ended July 31, 2015 on September 9, 2015 after market and will host a conference call and webcast at 1:30 PM Pacific Daylight Time (4:30 PM Eastern Daylight Time). Peregrine's senior management will discuss financial results for the first quarter and review the recent progress of its clinical development programs.
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)

AstraZeneca and Peregrine Pharmaceuticals to Collaborate on Immuno-Oncology Combination Clinical Trial
GlobeNewswire - Mon Aug 24, 1:05AM CDT
AstraZeneca (NYSE:AZN) and Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that they have entered into a cancer immunotherapy clinical trial collaboration. The collaboration will evaluate Peregrine's investigational phosphatidylserine (PS)-signaling pathway inhibitor, bavituximab, in combination with AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736). The planned Phase I/Ib trial will evaluate the safety and efficacy of bavituximab in combination with durvalumab in multiple solid tumors.
PPHMP: 22.92 (+0.25), AZN: 32.81 (-0.40), PPHM: 0.36 (unch)

Peregrine Pharmaceuticals Reports Fourth Quarter and Year-End Fiscal Year 2015 Financial Results and Recent Developments
GlobeNewswire - Tue Jul 14, 3:05PM CDT
-- Phase III SUNRISE Clinical Trial on Track to Complete Patient Enrollment by Calendar Year-End 2015 -
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 119

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
HONOR Leads in China, Eyes Middle East Market

Updated Category News Views 78

A Force to be Reckoned With Talk about making waves—HONOR's got the bragging rights now. Sitting pretty at the top among Android smartphone brands in China ain't no small feat. We're looking at a snazzy 12.04% market share for October 2026, all thanks to selling a cool 2.573 million units. The kicker? This ain't even their full potential. They're hustling hard in the...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 360

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Fortvita's Zybrivo Gains CHMP Nod: A European Leap

Updated Category News Views 50

It's not every day you're reading about a biotech making a ground-breaking shift off Chinese shores, but Fortvita's latest breakthrough is worth noting. Their fancy immunotherapy, Zybrivo® (sintilimab), just snagged a nod from the CHMP, Europe's committee that guides many on the medicinal merry-go-round. This isn't just your run-of-the-mill nod either. We're talking...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 161

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 165

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 22

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 23

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched Over Designer Brands Inc. Stock Concerns

Updated Category News Views 169

Insights into Designer Brands Inc.'s Ongoing Investigation In recent developments, Pomerantz LLP has begun an investigation focusing on Designer Brands Inc. and its operations within the retail space. Designer Brands Inc. is a prominent name in the footwear and apparel industry, known for its brand offerings and retail presence. Investors should pay close attention to...

Continue Reading
TECNO Unveils Innovative AI-Powered MEGAPAD Pro Experience

Updated Category News Views 338

Introducing the TECNO MEGAPAD Pro: A Game Changer in Tablet Technology TECNO has taken a monumental step in the tech world with the launch of the MEGAPAD Pro, an innovative tablet designed as the "Essential AI Tablet." This groundbreaking device boasts a remarkable 12-inch 2K eye-care display that prioritizes user health without compromising on functionality. Equipped...

Continue Reading
Vestis Corporation Faces Legal Scrutiny Amid Investor Concerns

Updated Category News Views 194

Vestis Corporation Under Investigation for Securities Violations Faruqi & Faruqi, LLP, a prominent national law firm specializing in securities litigation, is reaching out to investors involved with Vestis Corporation regarding potential legal claims. Investors who have faced significant financial losses while holding Vestis securities are encouraged to connect with the...

Continue Reading
AerCap's Milestone: First Boeing 777-300ERSF for Fly Meta

Updated Category News Views 239

AerCap's Milestone Delivery of the Boeing 777-300ERSF AerCap Holdings N.V. (NYSE: AER) has recently marked a significant milestone in aviation leasing by successfully delivering the first Boeing 777-300ERSF converted aircraft to Fly Meta Leasing Co., Ltd. This notable event represents not just a transaction, but a transformative step in the cargo aviation sector. The New...

Continue Reading
Exploring Aitech's Groundbreaking AI-Enabled Picosatellite Technology

Updated Category News Views 436

Aitech Introduces a Revolutionary AI-Enabled Picosatellite Platform The IQSat brings advanced AI capabilities in a cost-effective platform for low Earth orbit missions, enabling previously unreachable actionable data and insights. At a recent event, Aitech, a prominent provider of robust embedded systems tailored for military and aerospace applications, unveiled its...

Continue Reading